Alvotech (ALVO) Short-Term Debt repayments (2022 - 2026)
Alvotech's (ALVO) quarterly Short-Term Debt repayments came in at -$3.2 million in Q1 2026, down 38.97% YoY from -$5.2 million in Q1 2025, and down 164.34% on a QoQ basis from $4.9 million in Q3 2025.
Alvotech (ALVO) Short-Term Debt repayments (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has 5 years of Short-Term Debt repayments data on file, last reported at -$3.2 million in Q1 2026.
- Quarterly Short-Term Debt repayments fell 38.97% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 68.69% YoY) and the FY2021 annual result came in at -$7.4 million, down 20.75% from the prior year.
- Short-Term Debt repayments slipped to -$3.2 million in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of $4.9 million in Q3 2025 to a low of -$11.1 million in Q4 2022.
- A 5-year average of -$3.0 million and a median of -$2.4 million in 2024 frame the typical range for Short-Term Debt repayments.
- Annual changes were most pronounced in 2023 — Short-Term Debt repayments increased 25.82% — and 2024, when it slumped 53.31%.
- Tracing ALVO's Short-Term Debt repayments over 5 years: stood at -$11.1 million in 2022, then advanced by 25.82% to -$8.3 million in 2023, then retreated by 23.32% to -$10.2 million in 2024, then soared by 148.21% to $4.9 million in 2025, then slumped by 164.34% to -$3.2 million in 2026.
- The last three Short-Term Debt repayments figures came in at -$3.2 million (Q1 2026), $4.9 million (Q3 2025), and -$2.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Repayment (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alvotech | 1.23 Bn | 1.23 Bn | 5.09 Mn | -3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.16 Mn |
| Mar 31, 2026 | -3.16 Mn |
| Sep 30, 2025 | 4.92 Mn |
| Sep 30, 2025 | 4.92 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Mar 31, 2025 | -2.28 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Sep 30, 2024 | 4.82 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -2.34 Mn |
| Mar 31, 2024 | -2.34 Mn |
| Dec 31, 2023 | -8.27 Mn |
| Dec 31, 2023 | -8.27 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Jun 30, 2023 | -2.18 Mn |